EGLU
EGLU
EGLU (pronounced: e-g-l-u), also known as Evogliptin, is an antidiabetic drug used in the treatment of type 2 diabetes. It belongs to the class of drugs known as Dipeptidyl peptidase-4 inhibitors or DPP-4 inhibitors.
Pronunciation
EGLU is pronounced as "e-g-l-u".
Etymology
The term "EGLU" is an acronym derived from the drug's generic name, Evogliptin. The name "Evogliptin" is a combination of "evo", which is derived from the Latin word "evolutio" meaning development or progress, and "gliptin", a common suffix used for drugs in the DPP-4 inhibitor class.
Usage
EGLU is used in the management of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which in turn increases the levels of incretin hormones in the body. These hormones help to regulate blood sugar levels by increasing insulin production and decreasing glucagon production.
Related Terms
- Antidiabetic drug: A class of drugs used to treat diabetes.
- Dipeptidyl peptidase-4 inhibitors: A class of drugs that work by inhibiting the enzyme DPP-4, which increases the levels of incretin hormones in the body.
- Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose).
- Incretin hormones: Hormones that help to regulate blood sugar levels by increasing insulin production and decreasing glucagon production.
External links
- Medical encyclopedia article on EGLU
- Wikipedia's article - EGLU
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski